Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Reinaldo Acevedo, Xilian Bai, Ray Borrow, Dominique A. Caugant, Josefina Carlos, Mehmet Ceyhan, Hannah Christensen, Yanet Climent, Philippe De Wals, Ener Cagri Dinleyici, Gabriela Echaniz-Aviles, Ahmed Hakawi, Hajime Kamiya, Andromachi Karachaliou, Jay Lucidarme, Susan Meiring, Konstantin Mironov, Marco A. P. Sáfadi, Zhujun Shao, Vinny Smith, Robert Steffen, Bianca Stenmark, Muhamed-Kheir Taha, Caroline Trotter, Julio A. Vázquez & Bingqing Zhu. (2019) The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: Epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations. Expert Review of Vaccines 18:1, pages 15-30.
Read now
Read now
Ray Borrow & Elizabeth Miller. (2006) Long-term protection in children with meningococcal C conjugate vaccination: lessons learned. Expert Review of Vaccines 5:6, pages 851-857.
Read now
Read now
Articles from other publishers (24)
Peter Murphy, Sebastian Hinde, Helen Fulbright, Louise Padgett & Gerry Richardson. (2023) Methods of assessing value for money of UK-based early childhood public health interventions: a systematic literature review. British Medical Bulletin 145:1, pages 88-109.
Crossref
Crossref
Michael L. Jackson, Alpha Oumar Diallo, Isaie Médah, Brice Wilfried Bicaba, Issaka Yaméogo, Daouda Koussoubé, Rasmata Ouédraogo, Lassané Sangaré & Sarah A. Mbaeyi. (2018) Initial validation of a simulation model for estimating the impact of serogroup A Neisseria meningitidis vaccination in the African meningitis belt. PLOS ONE 13:10, pages e0206117.
Crossref
Crossref
Andrew R Gorringe. (2016) The difficult road to new vaccines for pertussis and serogroup B meningococcal disease. Journal of Chemical Technology & Biotechnology 91:1, pages 9-15.
Crossref
Crossref
Pippa Scott, Sereina A. Herzog, Kari Auranen, Ron Dagan, Nicola Low, Matthias Egger & Janneke C.M. Heijne. (2014) Timing of bacterial carriage sampling in vaccine trials: A modelling study. Epidemics 9, pages 8-17.
Crossref
Crossref
Ray Borrow, Raquel Abad, Caroline Trotter, Fiona R.M. van der Klis & Julio A. Vazquez. (2013) Effectiveness of meningococcal serogroup C vaccine programmes. Vaccine 31:41, pages 4477-4486.
Crossref
Crossref
Martin C. J. Maiden. (2013) The impact of protein-conjugate polysaccharide vaccines: an endgame for meningitis?. Philosophical Transactions of the Royal Society B: Biological Sciences 368:1623, pages 20120147.
Crossref
Crossref
J. L. SIMPSON & M. G. ROBERTS. (2013) MODELLING THE EFFECT OF VACCINATION ON THE MENINGOCOCCAL B EPIDEMIC IN NEW ZEALAND. The ANZIAM Journal 54:1-2, pages 74-88.
Crossref
Crossref
Patricia Coelho de Soarez, Ana Marli C. Sartori, Laura de Andrade Lagoa Nóbrega, Alexander Itria & Hillegonda Maria Dutilh Novaes. (2011) Cost-Effectiveness Analysis of a Universal Infant Immunization Program with Meningococcal C Conjugate Vaccine in Brazil. Value in Health 14:8, pages 1019-1027.
Crossref
Crossref
Philip C. S. de Whalley, Matthew D. Snape, Dominic F. Kelly, Carly Banner, Susan Lewis, Linda Diggle, Tessa M. John, Ly-Mee Yu, Omar Omar, Astrid Borkowski & Andrew J. Pollard. (2011) Persistence of Serum Bactericidal Antibody One Year After a Booster Dose of Either a Glycoconjugate or a Plain Polysaccharide Vaccine Against Serogroup C Neisseria meningitidis Given to Adolescents Previously Immunized With a Glycoconjugate Vaccine. Pediatric Infectious Disease Journal 30:11, pages e203-e208.
Crossref
Crossref
Ulrich Vogel & Heike Claus. (2010)
Vaccine development against
Neisseria meningitidis
. Microbial Biotechnology 4:1, pages 20-31.
Crossref
Crossref
Teresa L. Kauf. (2010) Methodological Concerns with Economic Evaluations of Meningococcal Vaccines. PharmacoEconomics 28:6, pages 449-461.
Crossref
Crossref
Helen Campbell, Nick Andrews, Ray Borrow, Caroline Trotter & Elizabeth Miller. (2010) Updated Postlicensure Surveillance of the Meningococcal C Conjugate Vaccine in England and Wales: Effectiveness, Validation of Serological Correlates of Protection, and Modeling Predictions of the Duration of Herd Immunity. Clinical and Vaccine Immunology 17:5, pages 840-847.
Crossref
Crossref
S. A. Halperin, F. Diaz-Mitoma, P. Dull, A. Anemona & F. Ceddia. (2009) Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlers. European Journal of Clinical Microbiology & Infectious Diseases 29:3, pages 259-267.
Crossref
Crossref
Ray Borrow, Nick Andrews, Helen Findlow, Pauline Waight, Joanna Southern, Annette Crowley-Luke, Lorraine Stapley, Anna England, Jamie Findlow & Elizabeth Miller. (2010)
Kinetics of Antibody Persistence following Administration of a Combination Meningococcal Serogroup C and
Haemophilus influenzae
Type b Conjugate Vaccine in Healthy Infants in the United Kingdom Primed with a Monovalent Meningococcal Serogroup C Vaccine
. Clinical and Vaccine Immunology 17:1, pages 154-159.
Crossref
Crossref
U. Wiedermann. (2009) Unterschiedliche Impfschemata in EuropaVarying vaccination schedules. Monatsschrift Kinderheilkunde 157:8, pages 743-750.
Crossref
Crossref
David Salisbury. (2009) Immunisation in the UK: protected for the future. Clinical Medicine 9:3, pages 261-263.
Crossref
Crossref
Helen Campbell, Ray Borrow, David Salisbury & Elizabeth Miller. (2009) Meningococcal C conjugate vaccine: The experience in England and Wales. Vaccine 27, pages B20-B29.
Crossref
Crossref
Kirsten P. Perrett, Matthew D. Snape, Karen J. Ford, Tessa M. John, Ly-Mee M. Yu, Joanne M. Langley, Shelly McNeil, Peter M. Dull, Francesca Ceddia, Alessandra Anemona, Scott A. Halperin, Simon Dobson & Andrew J. Pollard. (2009) Immunogenicity and Immune Memory of a Nonadjuvanted Quadrivalent Meningococcal Glycoconjugate Vaccine in Infants. Pediatric Infectious Disease Journal 28:3, pages 186-193.
Crossref
Crossref
Andrew J. Pollard, Kirsten P. Perrett & Peter C. Beverley. (2009) Maintaining protection against invasive bacteria with protein–polysaccharide conjugate vaccines. Nature Reviews Immunology 9:3, pages 213-220.
Crossref
Crossref
Siggeir F. Brynjolfsson, Stefania P. Bjarnarson, Elena Mori, Giuseppe Del Giudice & Ingileif Jonsdottir. (2008) Neonatal immune response and serum bactericidal activity induced by a meningococcal conjugate vaccine is enhanced by LT-K63 and CpG2006. Vaccine 26:35, pages 4557-4562.
Crossref
Crossref
EJ Dasbach, RP Insinga & EH Elbasha. (2008) The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK. BJOG: An International Journal of Obstetrics & Gynaecology 115:8, pages 947-956.
Crossref
Crossref
Barbara Baudner & Rino Rappuoli. 2008. Immunity Against Mucosal Pathogens. Immunity Against Mucosal Pathogens
323
365
.
David S Stephens, Brian Greenwood & Petter Brandtzaeg. (2007) Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. The Lancet 369:9580, pages 2196-2210.
Crossref
Crossref
B.A.M. van der Zeijst, M.I. Dijkman, W. Luytjes, A.J.W. van Alphen & G.P.J.M van den Dobbelsteen. (2007) On the design of national vaccination programmes. Vaccine 25:16, pages 3143-3145.
Crossref
Crossref